AHA today urged Congress and the administration to take immediate action to rein in the rising cost of drugs, including passing the Creating and Restoring Equal Access to Equivalent Samples Act and H.R. 4392. “Spending on pharmaceuticals has increased dramatically over the past several years, and the primary driver is higher prices,” AHA Executive Vice President Tom Nickels told the House Energy and Commerce Health Subcommittee at a hearing examining how the drug supply chain affects pharmaceutical costs, access and delivery. The CREATES Act would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief, while H.R. 4392 would prevent the Centers for Medicare & Medicaid Services from reducing Medicare payments for hospital outpatient drugs under the 340B drug savings program by nearly 30% effective Jan. 1. “The 340B program permits safety-net hospitals that care for communities with a high number of low-income and uninsured patients to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive service,” Nickels told the committee.

Headline
A bipartisan group of senators Aug. 5 introduced the Supporting Underserved and Strengthening Transparency, Accountability and Integrity Now and for the Future…
Headline
The Department of Health and Human Services today issued a notice announcing a revised 340B Rebate Model Pilot Program, allowing qualifying drug manufacturers…
Headline
The U.S. District Court for the District of Columbia July 21 upheld a lower court’s decision that Section 340B of the Public Health Service Act does not …
Headline
The AHA July 14 urged the Health Resources and Services Administration to revise its estimate of the administrative burden associated with the agency’s…
Headline
The AHA today filed a friend-of-the-court brief supporting the Department of Health and Human Services’ motion to dismiss AbbVie’s lawsuit …
Headline
The Health Resources and Services Administration announced that 340B covered entities purchased $100 billion in outpatient drugs under the federal 340B Drug…